亚太药业: 2025年半年度报告摘要

Core Viewpoint - Zhejiang Yatai Pharmaceutical Co., Ltd. reported a significant decline in revenue while achieving a substantial increase in net profit for the first half of 2025, indicating a shift in financial performance dynamics [1][2]. Financial Performance - The company's operating revenue for the reporting period was CNY 152.07 million, a decrease of 31.48% compared to CNY 221.93 million in the same period last year [1]. - Net profit attributable to shareholders reached CNY 105.18 million, marking an increase of 1,820.97% from CNY 5.48 million in the previous year [1]. - The net profit after deducting non-recurring gains and losses was CNY -48.86 million, a decline of 524.31% compared to CNY -7.83 million in the same period last year [1]. - The basic earnings per share rose to CNY 0.14, up 1,300% from CNY 0.01 [1]. - The weighted average return on equity was 10.01%, compared to 0.94% in the previous year [1]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1.24 billion, down 11.35% from CNY 1.40 billion at the end of the previous year [1]. - The net assets attributable to shareholders were CNY 1.13 billion, an increase of 16.15% from CNY 972.18 million [2]. - The debt-to-asset ratio improved to 9.14% from 30.65% in the previous year [3]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 55,101 [2]. - Ningbo Fubon Holdings Group Co., Ltd. remained the controlling shareholder with an 11.99% stake [2]. Significant Events - The company completed the sale of its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., for a total consideration of CNY 175 million, which included the assumption of debts [4][5]. - The first payment of CNY 30 million was received on March 31, 2025, and the second payment of CNY 145 million was received on June 25, 2025 [5].